March 29th 2024
A phase 2a open-label study found BL-003 for treatment-resistant depression was well-tolerated and any acute effects resolved on average in less than 2 hours.
2024 USCAP Satellite Symposia
March 25-27, 2024
Register Now!
FAQs in Peanut Allergy: Exploring Unanswered Questions Following Allergy Meeting Updates
View More
FAQs in MS: Exploring Provocative Questions From MS Meeting Updates
View More
BURST CME™: Taking ALS Management to the Next Level
View More
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Expert Illustrations and Commentaries™: Evaluating the Potential for Novel Mechanistic Approaches to Overcome Clinical Gaps in the Care of Patients with LR-MDS
View More
Community Practice Connections™: Guidebook for Community Oncology NSCLC Treating Teams to Administer EGFR Exon 20-Targeted Regimens
View More
Diabetes Dialogue: All Things AID at ATTD 2024
March 28th 2024In this episode, all things AID from the 17th annual ATTD, including updates from Insulet Corporation and Omnipod, study data from the Control IQ algorithm, the SMASH study, and a peak into the future with the Neural Network AID algorithm.
Beyond Colonoscopy: Shifting Incidence, Mortality Prompts New Era of Colorectal Cancer Screening
March 28th 2024The recent rise in colorectal cancer incidence and mortality in younger patients has sparked a serious discussion about strategies to increase screening uptake and adherence, raising questions about the role of noninvasive tests versus the traditional “gold standard,” colonoscopy.
Qazi Corner, Edition 5: Tofacitinib, Fenofibrates, Pouchitis Guidelines and BLUE-C
March 28th 2024The first quarterly issue of 2024 reviews a promising JAK inhibitor for acute severe ulcerative colitis, fenofibrates in PBC, new recommendations from the AGA, and a next generation multi-target DNA stool test for detecting colorectal cancer.